Chondroitin Sulfate, Glucosamine, And Manganese Ascorbate

Verify with FDA CVM →

28 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
28
Total Reports
0
Deaths Reported
0.0%
Death Rate

Active Ingredients

Chondroitin Sulfate, Glucosamine, And Manganese Ascorbate

Administration Routes

Unknown

Species Affected

Dog 24
Horse 4

Most Affected Breeds

Retriever - Labrador 6
Retriever - Golden 5
Warmblood (unspecified) 2
Rottweiler 1
Schnauzer - Giant 1
Dog (unknown) 1
Collie (unspecified) 1
Shepherd Dog - Australian 1
Whippet 1
Thoroughbred 1

Most Reported Reactions

Vomiting 10
Diarrhoea 6
Lethargy (see also Central nervous system depression in Neurological) 5
Pancreatitis 3
Not eating 3
Incorrect route of drug administration 3
Reluctant to move 3
Injection site swelling 3
Muscle stiffness 3
Lethargy (see also Central nervous system depression in 'Neurological') 2
Vocalisation 2
Unable to rise 2

Outcome Breakdown

Recovered/Normal
16 (57.1%)
Outcome Unknown
9 (32.1%)
Ongoing
3 (10.7%)

Data Summary

Metric Value
Total adverse event reports 28
Reports involving death 0
Case-fatality rate (reported events) 0.0%
Distinct species in reports 2
Distinct breeds in reports 18
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Chondroitin Sulfate, Glucosamine, And Manganese Ascorbate Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 28 adverse event reports referencing Chondroitin Sulfate, Glucosamine, And Manganese Ascorbate, including 0 reports in which the animal died — a 0.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Chondroitin Sulfate, Glucosamine, And Manganese Ascorbate. Reported administration route is Unknown. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Chondroitin Sulfate, Glucosamine, And Manganese Ascorbate reports are Dog (24 reports), Horse (4 reports), with Dog accounting for the largest share. Within those species, Retriever - Labrador (6), Retriever - Golden (5), Warmblood (unspecified) (2) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Chondroitin Sulfate, Glucosamine, And Manganese Ascorbate are Vomiting (10), Diarrhoea (6), Lethargy (see also Central nervous system depression in Neurological) (5), Pancreatitis (3). Of the 28 reports with a coded outcome, Recovered/Normal is the leading category at 57.1%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Chondroitin Sulfate, Glucosamine, And Manganese Ascorbate.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial